{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:40:09Z","timestamp":1794271209660,"version":"4.9.0"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"Supplement_6","license":[{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>SS is a chronic, autoimmune condition characterized by lymphocytic infiltration of the exocrine glands and B-cell dysfunction. Current treatment strategies are largely empirical and offer only symptomatic relief for patients. There are no proven treatments that alter disease progression or treat the systemic manifestations of disease. B-cell depletion is used in patients with systemic disease but its overall clinical efficacy has not been demonstrated in two large randomized controlled trials. Studies are now focussing on alternative strategies to target B-cells, including co-stimulation targets, with promising data. It is increasingly clear that clinical trials in SS will require patient stratification and relevant and sensitive outcome measures to identify successful treatment modalities.<\/jats:p>","DOI":"10.1093\/rheumatology\/keab466","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T19:20:33Z","timestamp":1623266433000},"page":"vi53-vi61","source":"Crossref","is-referenced-by-count":37,"title":["New developments in Sjogren\u2019s syndrome"],"prefix":"10.1093","volume":"60","author":[{"given":"Nishanthi","family":"Thalayasingam","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Baldwin","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Judd","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Fai","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust"},{"name":"Translation and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,24]]},"reference":[{"key":"2022042611173986000_keab466-B1","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sjogren's Syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"key":"2022042611173986000_keab466-B2","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/ard.2005.041186","article-title":"Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors","volume":"65","author":"Theander","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2022042611173986000_keab466-B3","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/rheumatology\/kep141","article-title":"Health-related quality of life, employment and disability in patients with Sjogren's syndrome","volume":"48","author":"Meijer","year":"2009","journal-title":"Rheumatology"},{"key":"2022042611173986000_keab466-B4","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/kex375","article-title":"The British Society for Rheumatology guideline for the management of adults with primary Sjogren's Syndrome","volume":"56","author":"Price","year":"2017","journal-title":"Rheumatology"},{"key":"2022042611173986000_keab466-B5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1172\/JCI0214121","article-title":"Association of BAFF\/BLyS overexpression and altered B-cell differentiation with Sjogren's syndrome","volume":"109","author":"Groom","year":"2002","journal-title":"J Clin Invest"},{"key":"2022042611173986000_keab466-B6","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1001\/jama.2013.278448","article-title":"Autoantibodies present before symptom onset in primary Sjogren syndrome","volume":"310","author":"Jonsson","year":"2013","journal-title":"JAMA"},{"key":"2022042611173986000_keab466-B7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1586\/1744666X.2014.891439","article-title":"B-cell hyperactivity in primary Sjogren's syndrome","volume":"10","author":"Kroese","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"2022042611173986000_keab466-B8","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/rheumatology\/key063","article-title":"B-cell activity markers are associated with different disease activity domains in primary Sjogren's syndrome","volume":"57","author":"James","year":"2018","journal-title":"Rheumatology"},{"key":"2022042611173986000_keab466-B9","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/art.10445","article-title":"Diminished peripheral blood memory B-cells and accumulation of memory B-cells in the salivary glands of patients with Sjogren's syndrome","volume":"46","author":"Hansen","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2022042611173986000_keab466-B10","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/art.20276","article-title":"Abnormalities in peripheral B-cell memory of patients with primary Sjogren's syndrome","volume":"50","author":"Hansen","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2022042611173986000_keab466-B11","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaut.2009.10.004","article-title":"Characteristics of the minor salivary gland infiltrates in Sjogren's syndrome","volume":"34","author":"Christodoulou","year":"2010","journal-title":"J Autoimmun"},{"key":"2022042611173986000_keab466-B12","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1002\/art.11311","article-title":"Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome","volume":"48","author":"Salomonsson","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2022042611173986000_keab466-B13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/1529-0131(199902)42:2<240::AID-ANR5>3.0.CO;2-I","article-title":"Analysis of V(H)-D-J(H) gene transcripts in B-cells infiltrating the salivary glands and lymph node tissues of patients with Sjogren's syndrome","volume":"42","author":"Gellrich","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2022042611173986000_keab466-B14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.semarthrit.2013.04.004","article-title":"Malignant lymphoma in primary Sjogren's syndrome: an update on the pathogenesis and treatment","volume":"43","author":"Routsias","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"2022042611173986000_keab466-B15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2020-218599","article-title":"Efficacy and safety of abatacept in active primary Sjogren's syndrome: results of a phase III, randomised, placebo-controlled trial","volume":"80","author":"Baer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022042611173986000_keab466-B16","doi-asserted-by":"crossref","first-page":"E153","DOI":"10.1016\/S2665-9913(19)30160-2","article-title":"Abatacept treatment for patients with early active primary Sjogren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)","volume":"2","author":"van Nimwegen","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2022042611173986000_keab466-B17","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","article-title":"Abatacept treatment reduces disease activity in early primary Sjogren's syndrome (open-label proof of concept ASAP study)","volume":"73","author":"Meiners","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022042611173986000_keab466-B18","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2022042611173986000_keab466-B19","doi-asserted-by":"crossref","first-page":"E142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"ssessment of the anti-CD40 antibody iscalimab in patients with primary Sjogren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2022042611173986000_keab466-B20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sjogren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"2022042611173986000_keab466-B21","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren's syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022042611173986000_keab466-B22","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2022042611173986000_keab466-B23","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/art.22536","article-title":"Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20)","volume":"57","author":"Devauchelle-Pensec","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2022042611173986000_keab466-B24","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2022042611173986000_keab466-B25","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2022042611173986000_keab466-B26","doi-asserted-by":"crossref","first-page":"R172","DOI":"10.1186\/ar4359","article-title":"Efficacy and safety of rituximab treatment in early primary Sjogren's syndrome: a prospective, multi-center, follow-up study","volume":"15","author":"Carubbi","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2022042611173986000_keab466-B27","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/art.39088","article-title":"Brief report: ultrasonographic assessment of salivary gland response to rituximab in primary Sjogren's syndrome","volume":"67","author":"Jousse-Joulin","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2022042611173986000_keab466-B28","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1136\/annrheumdis-2015-208304","article-title":"Towards personalised treatment in primary Sjogren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment","volume":"75","author":"Delli","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022042611173986000_keab466-B29","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/art.22603","article-title":"BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome","volume":"56","author":"Pers","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2022042611173986000_keab466-B30","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1136\/annrheumdis-2013-203447","article-title":"Predominantly proinflammatory cytokines decrease after B-cell depletion therapy in patients with primary Sjogren's syndrome","volume":"72","author":"Pollard","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022042611173986000_keab466-B31","doi-asserted-by":"crossref","first-page":"e85-94","DOI":"10.1016\/S2665-9913(19)30042-6","article-title":"Symptom-based stratification of patients with primary Sj\u00f6gren\u2019s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials","volume":"1","author":"Tarn","year":"2019","journal-title":"Lancet Rheumatology"},{"key":"2022042611173986000_keab466-B32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022042611173986000_keab466-B33","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/acr.22968","article-title":"Treatment guidelines for rheumatologic manifestations of Sjogren's syndrome: use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain","volume":"69","author":"Carsons","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2022042611173986000_keab466-B34","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/14397595.2018.1438093","article-title":"Clinical practice guideline for Sjogren's syndrome 2017","volume":"28","author":"Sumida","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2022042611173986000_keab466-B35","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/annrheumdis-2011-200086","article-title":"Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry","volume":"71","author":"Mekinian","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2022042611173986000_keab466-B36","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/annrheumdis-2012-202293","article-title":"Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry","volume":"72","author":"Gottenberg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022042611173986000_keab466-B37","doi-asserted-by":"crossref","first-page":"e0150749","DOI":"10.1371\/journal.pone.0150749","article-title":"Rituximab effectiveness and safety for treating primary Sjogren's syndrome (pSS): systematic review and meta-analysis","volume":"11","author":"Souza","year":"2016","journal-title":"PLoS One"},{"key":"2022042611173986000_keab466-B38","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1084\/jem.192.10.1453","article-title":"BAFF mediates survival of peripheral immature B lymphocytes","volume":"192","author":"Batten","year":"2000","journal-title":"J Exp Med"},{"key":"2022042611173986000_keab466-B39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.coi.2005.04.005","article-title":"The role of APRIL and BAFF in lymphocyte activation","volume":"17","author":"Schneider","year":"2005","journal-title":"Curr Opin Immunol"},{"key":"2022042611173986000_keab466-B40","first-page":"2249","article-title":"Efficacy and safety of belimumab given for 12 months in primary Sjogren's syndrome: the BELISS open-label phase II study","volume":"54","author":"De Vita","year":"2015","journal-title":"Rheumatology"},{"key":"2022042611173986000_keab466-B41","first-page":"311","article-title":"Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjogren's syndrome: follow-up after the end of the phase II open-label BELISS study","volume":"34","author":"Quartuccio","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2022042611173986000_keab466-B42","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/annrheumdis-2012-202071","article-title":"Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial","volume":"72","author":"Pollard","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022042611173986000_keab466-B43","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sjogren's syndrome with ianalumab (VAY736) targeting B-cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"Dorner","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022042611173986000_keab466-B44","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/ar2018","article-title":"Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I\/II study","volume":"8","author":"Steinfeld","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"2022042611173986000_keab466-B45","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/art.40425","article-title":"Efficacy of epratuzumab, an anti-CD22 monoclonal IgG antibody, in systemic lupus erythematosus patients with associated Sjogren's syndrome: post hoc analyses from the EMBODY trials","volume":"70","author":"Gottenberg","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2022042611173986000_keab466-B46","first-page":"317","article-title":"Abatacept treatment of patients with primary Sjogren's syndrome results in a decrease of germinal centres in salivary gland tissue","volume":"35","author":"Haacke","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2022042611173986000_keab466-B47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/1074-7613(94)90095-7","article-title":"The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation","volume":"1","author":"Kawabe","year":"1994","journal-title":"Immunity"},{"key":"2022042611173986000_keab466-B48","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/annrheumdis-2018-213929","article-title":"Blockade of CD40-CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD\/ShiLtJ mouse model of Sjogren's syndrome","volume":"78","author":"Wieczorek","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022042611173986000_keab466-B49","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1046\/j.1365-2249.2002.01752.x","article-title":"CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sjogren's syndrome patients indicating their intrinsic activation","volume":"127","author":"Dimitriou","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"2022042611173986000_keab466-B50","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1191\/0961203304lu1032oa","article-title":"Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients","volume":"13","author":"Sidiropoulos","year":"2004","journal-title":"Lupus"},{"key":"2022042611173986000_keab466-B51","article-title":"Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised placebo-controlled trial","author":"Felten","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022042611173986000_keab466-B52","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/rheumatology\/keaa508","article-title":"Burden of illness among subgroups of patients with primary Sjogren's syndrome and systemic involvement","volume":"60","author":"Gairy","year":"2021","journal-title":"Rheumatology"},{"key":"2022042611173986000_keab466-B53","doi-asserted-by":"crossref","first-page":"102690","DOI":"10.1016\/j.autrev.2020.102690","article-title":"Minor salivary gland biopsy: its role in the classification and prognosis of Sjogren's syndrome","volume":"19","author":"Bautista-Vargas","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2022042611173986000_keab466-B54","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sjogren's syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022042611173986000_keab466-B55"},{"key":"2022042611173986000_keab466-B56","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/acr.23839","article-title":"Juvenile Sjogren's syndrome: clinical characteristics with focus on salivary gland ultrasonography","volume":"72","author":"Hammenfors","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2022042611173986000_keab466-B57","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1136\/annrheumdis-2019-216588","article-title":"Salivary gland epithelial cells from patients with Sjogren's syndrome induce B-lymphocyte survival and activation","volume":"79","author":"Riviere","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022042611173986000_keab466-B58","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/art.41558","article-title":"Interleukin-7\/Interferon axis drives T-cell and salivary gland epithelial cell interactions in Sjogren's syndrome","volume":"73","author":"Riviere","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2022042611173986000_keab466-B59","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s00296-019-04354-0","article-title":"Fatigue in primary Sjogren's syndrome (pSS) is associated with lower levels of proinflammatory cytokines: a validation study","volume":"39","author":"Davies","year":"2019","journal-title":"Rheumatol Int"},{"key":"2022042611173986000_keab466-B60","doi-asserted-by":"crossref","first-page":"e000282","DOI":"10.1136\/rmdopen-2016-000282","article-title":"Fatigue in primary Sjogren's syndrome is associated with lower levels of proinflammatory cytokines","volume":"2","author":"Howard Tripp","year":"2016","journal-title":"RMD Open"},{"key":"2022042611173986000_keab466-B61","doi-asserted-by":"crossref","first-page":"e0143970","DOI":"10.1371\/journal.pone.0143970","article-title":"A transcriptional signature of fatigue derived from patients with primary Sjogren's syndrome","volume":"10","author":"James","year":"2015","journal-title":"PLoS One"},{"key":"2022042611173986000_keab466-B62","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2012-202863","article-title":"Health-related utility values of patients with primary Sjogren's syndrome and its predictors","volume":"73","author":"Lendrem","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022042611173986000_keab466-B63","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/rheumatology\/ker208","article-title":"Fatigue and depression predict physician visits and work disability in women with primary Sjogren's syndrome: results from a cohort study","volume":"51","author":"Westhoff","year":"2012","journal-title":"Rheumatology"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/Supplement_6\/vi53\/43463749\/keab466.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/Supplement_6\/vi53\/43463749\/keab466.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T11:45:36Z","timestamp":1650973536000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/Supplement_6\/vi53\/6482887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":63,"journal-issue":{"issue":"Supplement_6","published-online":{"date-parts":[[2021,12,24]]},"published-print":{"date-parts":[[2021,12,24]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab466","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,11,1]]}}}